BSE Live
Sep 05, 16:01Prev. Close
1035.25
Open Price
1035.65
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Sep 05, 15:56Prev. Close
1036.00
Open Price
1038.30
Bid Price (Qty.)
1044.10 (53)
Offer Price (Qty.)
0.00 (0)
Profit & Loss account of Aurobindo Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
INCOME | ||||||
Revenue From Operations [Gross] | 10,788.09 | 10,542.21 | 12,607.54 | 11,250.07 | 15,622.18 | |
Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Revenue From Operations [Net] | 10,788.09 | 10,542.21 | 12,607.54 | 11,250.07 | 15,622.18 | |
Total Operating Revenues | 10,933.30 | 10,645.64 | 12,792.28 | 11,287.14 | 15,823.68 | |
Other Income | 328.12 | 616.06 | 433.76 | 670.99 | 589.86 | |
Total Revenue | 11,261.42 | 11,261.70 | 13,226.04 | 11,958.13 | 16,413.54 | |
EXPENSES | ||||||
Cost Of Materials Consumed | 5,610.21 | 5,761.08 | 7,247.69 | 5,783.93 | 7,215.74 | |
Purchase Of Stock-In Trade | 65.13 | 203.40 | 89.23 | 16.81 | 26.09 | |
Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Changes In Inventories Of FG,WIP And Stock-In Trade | -67.66 | -116.23 | -466.00 | 45.51 | 2.99 | |
Employee Benefit Expenses | 1,063.07 | 980.56 | 1,641.88 | 1,600.04 | 1,735.42 | |
Finance Costs | 230.04 | 182.60 | 114.98 | 16.94 | 28.68 | |
Depreciation And Amortisation Expenses | 297.20 | 254.58 | 435.35 | 415.26 | 488.00 | |
Other Expenses | 1,704.98 | 1,592.79 | 2,548.56 | 2,367.45 | 2,723.61 | |
Total Expenses | 8,902.97 | 8,858.78 | 11,611.69 | 10,245.94 | 12,220.53 | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 2,358.45 | 2,402.92 | 1,614.35 | 1,712.19 | 4,193.01 | |
Exceptional Items | 0.00 | 0.00 | 0.00 | -74.71 | 0.00 | |
Profit/Loss Before Tax | 2,358.45 | 2,402.92 | 1,614.35 | 1,637.48 | 4,193.01 | |
Tax Expenses-Continued Operations | ||||||
Current Tax | 627.37 | 598.08 | 407.02 | 379.70 | 1,043.34 | |
Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Deferred Tax | -15.71 | -95.26 | -23.08 | -196.93 | 36.76 | |
Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Tax Expenses | 611.66 | 502.82 | 383.94 | 182.77 | 1,080.10 | |
Profit/Loss After Tax And Before ExtraOrdinary Items | 1,746.79 | 1,900.10 | 1,230.41 | 1,454.71 | 3,112.91 | |
Profit/Loss From Continuing Operations | 1,746.79 | 1,900.10 | 1,230.41 | 1,454.71 | 3,112.91 | |
Profit/Loss For The Period | 1,746.79 | 1,954.14 | 1,230.41 | 1,454.71 | 3,112.91 | |
OTHER ADDITIONAL INFORMATION | ||||||
EARNINGS PER SHARE | ||||||
Basic EPS (Rs.) | 29.97 | 33.35 | 21.00 | 24.83 | 53.13 | |
Diluted EPS (Rs.) | 29.97 | 33.35 | 21.00 | 24.83 | 53.13 | |
VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
Equity Share Dividend | 0.00 | 263.66 | 439.45 | 263.67 | 234.38 | |
Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Equity Dividend Rate (%) | 0.00 | 450.00 | 300.00 | 900.00 | 400.00 |
12.08.2025
Aurobindo Pharm Consolidated June 2025 Net Sales at Rs 7,868.14 crore, up 3.98% Y-o-Y
05.08.2025
Aurobindo Pharm Standalone June 2025 Net Sales at Rs 2,848.17 crore, up 15.78% Y-o-Y
27.05.2025
Aurobindo Pharm Standalone March 2025 Net Sales at Rs 2,731.99 crore, down 5.6% Y-o-Y
12.02.2025
Aurobindo Pharm Standalone December 2024 Net Sales at Rs 2,916.63 crore, up 8.34% Y-o-Y
14.07.2023
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
14.07.2023
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
13.07.2022
Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct
08.07.2022
Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL